C Difficile

Fecal microbes could help populations at risk of drug-resistant infections, such as patients who get organ transplants.

A genomic signature for endosporulation includes a gene coding for a protease, YabG, which in the model organism Bacillus subtilis is involved in assembly of the spore coat. We show that in the human pathogen Clostridioidesm difficile, YabG is critical for the assembly of the coat and exosporium lay …

### What you need to know A 42 year old man visits his general practitioner with a three month history of intermittent nausea and central chest discomfort, particularly after fatty and sweet meals. He occasionally has a bad taste in his mouth when he wakes up from sleep. His body mass index is 32, he has no significant medical history, and he takes no regular medications. After asking him about alarm symptoms, you make a diagnosis of gastro-oesophageal reflux disease. You are considering prescribing a proton pump inhibitor as a first line therapy. Prevalence of proton pump inhibitor (PPI) use is about 15% of the UK population, according to two primary care database studies.12 In 2022-23, 73 million NHS prescriptions for PPIs were dispensed in England at a cost of about £190 million, equating to 1.8% of total primary care prescription costs and 6% of all prescriptions dispensed.3 The two most commonly prescribed PPIs in England are omeprazole and lansoprazole, which were among the five most commonly dispensed drugs in 2020. There is strong evidence to support the use of PPIs across a range of indications.4 PPIs are used in the treatment of upper gastrointestinal disorders characterised by excessive acid production and damage to upper gastrointestinal tissue,5 and are also prescribed as gastroprotection for patients being treated with medications which increase the risk of ulceration, such as non-steroidal …

Researchers are homing in on a new connection between colon cancer and the infectious bacterium known as Clostridioides difficile, or C. diff.

Background The gram-negative anaerobe Clostridium difficile is the main infectious cause of pseudomembranous colitis and infectious diarrhea in hospitalized patients. Inflammatory bowel disea...

The curative potential and limitations of gut microbiome-based therapeutics in critical illnesses.

The Importance of a Broad Consortium of Bacteria for a Healthy Gastrointestinal tract: A Narrative Review of the Live Biotherapeutic Product REBYOTA

Background Clostridioides difficile infection (CDI) is a major cause of diarrhea in hospitalized adult patients. This study aims to evaluate the clinical characteristics, clinical cure, recur...

While many developments have been achieved with novel pharmacological treatments to manage IBD, ongoing research is required to confirm their effectiveness and safety in the paediatric age. Extending the licence of novel treatments to children will be crucial to tackle the increasing loss of respons …

Among 23 patients with multiply recurrent Clostridiodies difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effect …

Paediatric diarrhoea patients showed higher positivity rates than adult patients. Application of FAGIP for acute diarrhoea might lower unnecessary antimicrobial use.

Recent developments in sequencing technology and analytical approaches have allowed researchers to show that the healthy gut microbiome is very varied and capable of performing a wide range of tasks. The importance of gut microbiota in controlling immunological, neurological, and endocrine function …

SJT demonstrates remarkable efficacy in treating CDI in mice by not only effectively combating the infection but also restoring the intricate balance of gut microbiota and bile acid metabolism. Furthermore, promising indications suggest that SJT may have the potential to prevent CDI recurrence. Thes …

Our study highlights the dominance of Toxin EIA-negative CDI specimens in a clinical setting and the high frequency of known virulent ribotypes in these specimens. Therefore, a careful reevaluation of the clinical relevance of diagnostically-discrepant specimens particularly in the context of missed …

Acurx is a promising antibiotic company with perfect Phase 2a data in treating C. difficile infection. Find out why ACXP stock is a Buy.

Learn what a long-term study on antibiotic resistance in patients with periodontitis showed, and its implications for dentistry.

Kari A. Mergenhagen, PharmD, BCPS, BCIDP, discusses the potential of doxycycline in reducing C difficile infections among hospitalized patients with pneumonia. This interview delves into doxycycline's influence on patients with a prior C difficile history, demographic generalizability, exclusion criteria, and concerns regarding antibiotic resistance.

Microbiome treatments are taking off

With current first-in-line antibiotic therapy options associated with high levels of recurrent CDI, the availability of new generation targeted therapeutics can really impact treatment success. There are still unknowns about the long-term implications of these new CDI therapeutics, but efforts to ex …

Wnt signaling pathways are transmitted via 10 homologous frizzled receptors (FZD1-10) in humans. Reagents broadly inhibiting Wnt signaling pathways reduce growth and metastasis of many tumors, but their therapeutic development has been hampered by the side effect. Inhibitors targeting specific Wnt-F …

These findings highlight the predominance of HO-CDI and the need for further investigation into CO-CDI in the Indian context to identify at-risk populations. Utilizing standardized surveillance methods such as NHSN definitions can facilitate accurate disease burden estimation, trend monitoring, and …

The global microbiome therapeutics market is growing at a CAGR of 10.1% from 2022 to 2030.Pune, India, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Microbiome therapeutics, also referred to as microbiome-based therapies or interventions, are medical procedures that try to use the human microbiome's potential to treat and promote a variety of illnesses. In the healthcare and life science industries, microbiome therapeutics are a new and quickly expanding market. This market is being driven by advancements i

Our understanding of how the microbiota affects the balance between response to and failure of cancer treatment by modulating the tumour microenvironment and systemic immune system has advanced rapidly in recent years. Microbiota-targeting interventions in patients with cancer are an area of intensi …

Background: The modulating effects of probiotics and fecal microbiota transplantation (FMT) on gut flora and their direct antitumor effects remain unclear in dirty rats with established primary liver cancer. Materials & methods: Probiotics (VSL#3), FMT or tap water were administrat …

The advent of high-throughput 'omics' technologies has improved our knowledge of gut microbiome in human health and disease, including Alzheimer's disease (AD), a neurodegenerative disorder. Frequent bidirectional communications and mutual regulation exist between the gastrointestinal tract and the …

Inflammatory bowel disease (IBD) is a multifactorial disease, which is thought to be an interplay between genetic, environment, microbiota, and immune-mediated factors. Dysbiosis in the gut microbial composition, caused by antibiotics and diet, is closely related to the initiation and progression of …

Clostridioides difficile infection (CDI) is considered to be one of the most frequent causes of bacterial infectious diarrhea in nosocomial settings. The prolonged hospitalization in bed-ridden conditions and the frequent administration of antibiotic therapy are usually encountered among the …

The diverse bacterial populations within the symbiotic microbiota play a pivotal role in both health and disease. Microbiota modulates critical aspects of tumor biology including cell proliferation, invasion, and metastasis. This regulation occurs through mechanisms like enhancing genomic damage, hi …

Gut microbial dysbiosis in mice after surgery is a key mechanism leading to cognition dysfunction, which disrupts the intestinal barrier and metabolic abnormalities, resulting in neuroinflammation and dendritic spine loss. Intestinal barrier damage and high level of palmitic amide in old mice may be …